Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ) is a leading Chinese contract research organization (CRO) providing clinical trial services to pharmaceutical and biotech companies. As the biotech sector in China recovers from a funding drought, Tigermed is well-positioned to capture increased outsourcing demand. The company has a robust backlog of orders, and its focus on higher-margin functional service provider (FSP) and digital solutions is expected to drive margin expansion. With a net cash position and strong free cash flow generation, Tigermed offers a defensive balance sheet while participating in the secular growth of China’s drug development ecosystem.
12-Month Catalysts:
- Recovery in biotech financing and R&D spending in China, leading to new contract wins.
- Margin expansion from mix shift toward FSP and digital solutions, plus operating leverage.
- Potential regulatory tailwinds from China’s drug approval reforms and inclusion of innovative drugs in NRDL.
Key Risks:
- Geopolitical tensions and US-China decoupling could impact client relationships and access to US markets.
- Slower-than-expected recovery in biotech funding or increased competition from global CROs.
Risk Disclaimer: This is not personalized investment advice. Investing involves risk, including potential loss of principal. Past performance is not indicative of future results. Please conduct your own due diligence or consult a financial advisor before making investment decisions.